Prostate neuroendocrine neoplasm
disease diseaseOn this page
Also known as neuroendocrine neoplasm of prostateneuroendocrine neoplasm of prostate glandneuroendocrine neoplasm of the prostateneuroendocrine tumour of the prostateprostate gland NETprostate gland neuroendocrine neoplasmprostate gland neuroendocrine tumorprostate gland neuroendocrine tumor, well differentiated, low or intermediate gradeprostate gland neuroendocrine tumourprostate neuroendocrine carcinoma
Summary
Prostate neuroendocrine neoplasm (MONDO:0002477) is a cancer and 5 clinical trials. Top therapeutic interventions include cabazitaxel, lutetium oxodotreotide lu-177, and niraparib. A subtype of neuroendocrine neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | prostate neuroendocrine neoplasm |
| Mondo ID | MONDO:0002477 |
| DOID | DOID:2992 |
| NCIT | C5545 |
| UMLS | C1335515 |
| MedGen | 277537 |
| GARD | 0023144 |
| Anatomy (UBERON) | UBERON:0002367 |
| Is cancer (heuristic) | yes |
Also known as: neuroendocrine neoplasm of prostate · neuroendocrine neoplasm of prostate gland · neuroendocrine neoplasm of the prostate · neuroendocrine tumour of the prostate · prostate gland NET · prostate gland neuroendocrine neoplasm · prostate gland neuroendocrine tumor · prostate gland neuroendocrine tumor, well differentiated, low or intermediate grade · prostate gland neuroendocrine tumour · prostate neuroendocrine carcinoma · prostate neuroendocrine neoplasm
Data availability: 1 cell line.
Disease family
This is a subtype of neuroendocrine neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › neuroendocrine neoplasm › prostate neuroendocrine neoplasm
Related subtypes (13): paraganglioma, neuroendocrine carcinoma, ovarian neuroendocrine neoplasm, breast neuroendocrine neoplasm, carcinoid tumor, lung neuroendocrine neoplasm, laryngeal neuroendocrine neoplasm, middle ear neuroendocrine tumor, hereditary pheochromocytoma-paraganglioma, bronchial endocrine tumor, thymic neuroendocrine tumor, uterine corpus neuroendocrine neoplasm, digestive system neuroendocrine neoplasm
Subtypes (1): prostate small cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04592237 | PHASE2 | ACTIVE_NOT_RECRUITING | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer |
| NCT04709276 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer |
| NCT05691465 | PHASE2 | RECRUITING | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells |
| NCT03582475 | PHASE1 | ACTIVE_NOT_RECRUITING | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate |
| NCT06062745 | PHASE1 | RECRUITING | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABAZITAXEL | 4 | 2 |
| LUTETIUM OXODOTREOTIDE LU-177 | 4 | 1 |
| NIRAPARIB | 4 | 1 |
| CETRELIMAB | 3 | 1 |